Indonesia Lysosomal Storage Disorder Drugs Market to 2032
Overview
The Indonesia Lysosomal Storage Disorder Drugs Market is expected to reach a 231.90 USD Million by 2032 and is projected to grow at a CAGR of 10.30% from 2025 to 2032.
Indonesia Lysosomal Storage Disorder Drugs Market 2018-2032 USD Million
Indonesia Lysosomal Storage Disorder Drugs Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 116.74 USD Million
- Projected Market Size (2032): 231.90 USD Million
- CAGR (2025-2032): 10.30%
Key Findings of Indonesia Lysosomal Storage Disorder Drugs Market
- The Indonesia Lysosomal Storage Disorder Drugs Market was valued at 116.74 USD Million in 2024.
- The Indonesia Lysosomal Storage Disorder Drugs Market is likely to grow at a CAGR of 10.30% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Hospital Pharmacies in Distribution Channel Segment accounted for the largest share of the market with a revenue of 81.84 USD Million
- The fastest growing segment Imiglucerase in Drugs Segment grew Fastest with a CAGR of 12.50% during the forecast period from 2024 to 2032.
Indonesia Lysosomal Storage Disorder Drugs Market Scope
- Female
- Male
- Online Pharmacies
- Drugs Stores and Retail Pharmacies
- Hospital Pharmacies
- Geriatric
- Adults
- Pediatric
- Others
- Krabbe Disease
- Niemann-Pick Disease
- Mucopolysaccharidosis (MPS)
- Pompe Disease
- Fabry Disease
- Gaucher Disease
- Others
- Chaperone Therapy
- Substrate Reduction Therapy (SRT)
- Enzyme Replacement Therapy (ERT)
- Others
- Avalglucosidase Alfa
- Galsulfase
- Agalsidase Alpha
- Laronidase
- Taliglucerase Alfa
- Velaglucerase
- Alglucosidase Alpha
- Idursulfase
- Agalsidase Beta
- Imiglucerase
- Others
- Oral
- Subcutaneous (SC)
- Intravenous (IV)
Indonesia Lysosomal Storage Disorder Drugs Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2023 |
| Unit | Revenue in USD Million |
| Market Value in 2024 | 116.74 USD Million |
| Market Value in 2032 | 231.90 USD Million |
| CAGR (2025-2032) | 10.30% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Gender,Distribution Channel,Age Group,Type of Disorder,Type,Drugs,Route of Administration |
Regional Insights:
-
Leading Market (2024-2032): Indonesia, leading in terms of revenue 116.74 USD Million in 2024
- Key Country: Indonesia, leading in terms of revenue with value of 116.74 USD Million in 2024.
Segments and Scope
-
Indonesia Lysosomal Storage Disorder Drugs Market to 2032, By Gender
- Male is the largest segment in Indonesia Lysosomal Storage Disorder Drugs Market to 2032 with a revenue of 67.37 USD Million in the year 2024.
- Male is the Fastest growing segment in Indonesia Lysosomal Storage Disorder Drugs Market to 2032 with a Growth rate of 11.05 % in forecast period 2025-2032.
-
Indonesia Lysosomal Storage Disorder Drugs Market to 2032, By Distribution Channel
- Hospital Pharmacies is the largest segment in Indonesia Lysosomal Storage Disorder Drugs Market to 2032 with a revenue of 81.84 USD Million in the year 2024.
- Online Pharmacies is the Fastest growing segment in Indonesia Lysosomal Storage Disorder Drugs Market to 2032 with a Growth rate of 10.43 % in forecast period 2025-2032.
-
Indonesia Lysosomal Storage Disorder Drugs Market to 2032, By Age Group
- Pediatric is the largest segment in Indonesia Lysosomal Storage Disorder Drugs Market to 2032 with a revenue of 52.20 USD Million in the year 2024.
- Pediatric is the Fastest growing segment in Indonesia Lysosomal Storage Disorder Drugs Market to 2032 with a Growth rate of 11.25 % in forecast period 2025-2032.
-
Indonesia Lysosomal Storage Disorder Drugs Market to 2032, By Type of Disorder
- Gaucher Disease is the largest segment in Indonesia Lysosomal Storage Disorder Drugs Market to 2032 with a revenue of 44.11 USD Million in the year 2024.
- Gaucher Disease is the Fastest growing segment in Indonesia Lysosomal Storage Disorder Drugs Market to 2032 with a Growth rate of 11.16 % in forecast period 2025-2032.
-
Indonesia Lysosomal Storage Disorder Drugs Market to 2032, By Type
- Enzyme Replacement Therapy (ERT) is the largest segment in Indonesia Lysosomal Storage Disorder Drugs Market to 2032 with a revenue of 77.84 USD Million in the year 2024.
- Substrate Reduction Therapy (SRT) is the Fastest growing segment in Indonesia Lysosomal Storage Disorder Drugs Market to 2032 with a Growth rate of 10.17 % in forecast period 2025-2032.
-
Indonesia Lysosomal Storage Disorder Drugs Market to 2032, By Drugs
- Imiglucerase is the largest segment in Indonesia Lysosomal Storage Disorder Drugs Market to 2032 with a revenue of 30.19 USD Million in the year 2024.
- Imiglucerase is the Fastest growing segment in Indonesia Lysosomal Storage Disorder Drugs Market to 2032 with a Growth rate of 12.50 % in forecast period 2025-2032.
-
Indonesia Lysosomal Storage Disorder Drugs Market to 2032, By Route of Administration
- Intravenous (IV) is the largest segment in Indonesia Lysosomal Storage Disorder Drugs Market to 2032 with a revenue of 69.79 USD Million in the year 2024.
- Subcutaneous (SC) is the Fastest growing segment in Indonesia Lysosomal Storage Disorder Drugs Market to 2032 with a Growth rate of 9.74 % in forecast period 2025-2032.
Indonesia Lysosomal Storage Disorder Drugs Market Company Share Analysis
| Company Name |
|
||
| Takeda Pharmaceutical Company Limited | |||
| Pfizer Inc. | |||
| Sanofi | |||
| BioMarin | |||
| Amicus Therapeutics, Inc. | |||
Indonesia Lysosomal Storage Disorder Drugs Market Geographical Sales Distribution, 2018-2032 USD Million
Indonesia Lysosomal Storage Disorder Drugs Market Company Profiling
Industry Related Reports
Frequently Asked Questions
Indonesia Lysosomal Storage Disorder Drugs Market Scope
- Female
- Male
- Online Pharmacies
- Drugs Stores and Retail Pharmacies
- Hospital Pharmacies
- Geriatric
- Adults
- Pediatric
- Others
- Krabbe Disease
- Niemann-Pick Disease
- Mucopolysaccharidosis (MPS)
- Pompe Disease
- Fabry Disease
- Gaucher Disease
- Others
- Chaperone Therapy
- Substrate Reduction Therapy (SRT)
- Enzyme Replacement Therapy (ERT)
- Others
- Avalglucosidase Alfa
- Galsulfase
- Agalsidase Alpha
- Laronidase
- Taliglucerase Alfa
- Velaglucerase
- Alglucosidase Alpha
- Idursulfase
- Agalsidase Beta
- Imiglucerase
- Others
- Oral
- Subcutaneous (SC)
- Intravenous (IV)
Frequently Asked Questions
Indonesia Lysosomal Storage Disorder Drugs Market Company Profiling
Frequently Asked Questions
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.